In summary, HPS has been shown to improve the symptoms of diabetic neuropathy by upregulating Nrf2 and downregulating Keap1 protein, as well as inhibiting NF-κB and IL-1β expression. This evidence concerns the gene NFKB1 and Hermansky-Pudlak syndrome.